MAXIGESIC IV Drug Insight and U.S. Market Forecasts to 2032: In-depth Product Overview, Regulatory Milestones, Competitive Landscape Analysis, and SWOT Analysis
January 29, 2024 12:15 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Dual Mode-of-Action...
Hyloris annonce la soumission des données relatives au conditionnement de Maxigesic® IV demandées par la FDA aux Etats-Unis
April 18, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
- Données supplémentaires sur les substances extractibles et impuretés générées par un laboratoire accrédité situé en Amérique du Nord - Résultats analysés et évalués par des experts en toxicologie ...
Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA
April 18, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological expertsPotential regulatory approval for...
Hyloris annonce un partenariat commercial pour Maxigesic® IV dans 9 pays européens
January 24, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Signature d'un accord exclusif de licence et de distribution avec Salus Pharmaceuticals en Lituanie, Estonie, Lettonie, Croatie, Slovénie, Serbie, Macédoine du Nord, Monténégro et BosniePremiers...
Hyloris Announces Commercial Partnership for Maxigesic® IV in 9 European Countries
January 24, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Exclusive licensing and distribution agreement signed with Salus Pharmaceuticals in Lithuania, Estonia, Latvia, Croatia, Slovenia, Serbia, North Macedonia, Montenegro and BosniaFirst commercial...
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
March 05, 2021 01:00 ET
|
Hyloris Pharmaceuticals
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets Footprint across Europe now extended to a total of 20 EU member states ...
Hyloris announces approval of Maxigesic® IV in eight European countries
September 07, 2020 04:37 ET
|
Hyloris Pharmaceuticals
Hyloris announces approval of Maxigesic® IV in eight European countries Commercialization of Hyloris’ second marketed product to start in early 2021 Liège, Belgium – 7 September 2020 – Hyloris...